HCW Biologics (HCWB) Projected to Post Earnings on Wednesday

HCW Biologics (NASDAQ:HCWB) is expected to be announcing its results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $7.0120 million for the quarter.

HCW Biologics Stock Down 17.9%

Shares of NASDAQ:HCWB opened at $0.43 on Wednesday. HCW Biologics has a 52 week low of $0.39 and a 52 week high of $17.80. The company has a 50-day moving average price of $0.86 and a 200 day moving average price of $2.17. The company has a market cap of $1.50 million, a P/E ratio of -0.04 and a beta of 0.79.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $35.00.

Hedge Funds Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent SEC filing. 2.96% of the stock is currently owned by institutional investors and hedge funds.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.